PT  - JOURNAL ARTICLE
ED  - ,
TI  - Correction
AID  - 10.1136/dtb.30.23.92
DP  - 1992 Nov 09
TA  - Drug and Therapeutics Bulletin
PG  - 92--92
VI  - 30
IP  - 23
4099  - http://dtb.bmj.com/content/30/23/92.short
4100  - http://dtb.bmj.com/content/30/23/92.full
SO  - Drug Ther Bull1992 Nov 09; 30
AB  - In our article Gonadotrophin releasing hormone analogues for advanced prostate cancer (17 August, page 65) we warned that testosterone levels might rebound above normal if a dose of a depot preparation of a GnRH analogue missed. In fact if the dose is delayed by 2 weeks, serum testosterone concentrations may rise above the castration range in about 30% of patients but do not rise above normal.1 In the Practice Synopsis included in the article we mentioned that goserelin (Zoladex) was licensed for advanced prostate cancer and endometriosis but omitted to mention that it was also licensed for advanced breast cancer in pre- and peri-menopausal women.